Krystal Biotech (FRA:4KB) Beta: 0.7280 (As of Jun. 26, 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €303.60
GF Value €263.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Beta?

Krystal Biotech FRA:4KB +2.29% 58 Beta is 0.7280 as of Jun. 26, 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Krystal Biotech's Beta is 0.7280.


Krystal Biotech  (FRA:4KB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Krystal Biotech Beta Related Terms


Krystal Biotech Beta Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Beta Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.54 -0.67 0.82 0.51

Krystal Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.33 -0.59 0.51 -0.26

FRA:4KB vs NUVL, PRAX, TECH: Beta Comparison

For the Biotechnology subindustry, Krystal Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Beta falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7280 mean?
Krystal Biotech (FRA:4KB) has a Beta of 0.7280 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Krystal Biotech and its competitors.
Is Krystal Biotech's Beta too high?
Krystal Biotech's current Beta is 0.7280. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Beta compare to NUVL and PRAX?
Krystal Biotech's Beta of 0.7280 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Krystal Biotech and its competitors. Krystal Biotech's current Beta is 0.7280. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current Beta is 0.7280. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Beta is 0.7280 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Beta: 0.7280
  • GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€303.60
Price
€263.13
GF Value